36 results about "Recombinant immunotoxin" patented technology

Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.

The invention provides novel recombinant immunotoxins comprising domain III of cholix toxin and exotoxin from Vibrio cholerae. The present invention further provides methods for using the compositions of the present invention to (i) induce apoptosis in a cell bearing one or more surface markers (ii) inhibit unwanted growth, hyperproliferation or survival of a cell bearing one or more cell surface markers, (iii) treat a condition, such as a cancer, (iv) provide therapy for a mammal having developed antibodies to Pseudomonas exotoxin A, and (v) provide therapy for a mammal having developed a disease caused by the presence of cells bearing one or more cell surface marker.

The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using VB4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.

The present invention provides methods for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients using an anti-CD22 immunotoxin. The methods disclosed comprise administering to a pediatric patient in need of that treatment an effective dose of a recombinant immunotoxin comprising a variable light (V_L) chain linked to a variable heavy (V_H) which is genetically fused to a therapeutic moiety comprising a Pseudomonas exotoxin A PE38 fragment. The recombinant immunotoxin specifically binds CD22 thereby inhibiting the growth of CD22-expressing (CD22⁺) ALL cancer cells.

This invention belongs to anti-carcinoe mbryonic antigen recombination immuno toxin. It is concretely relates to said antigen immuno toxic with (Arg)9 based on pseudomonic extotoxin. Nucleuotide sequence code-connects ectotoxin and the antigen connecting peptide, contains the expressing carrier of the sequence and the xeno-cell of the sequence and the utilization of the prevention and cure of tumor.

A high-specificity recombinant immunotoxin for preventing and treating autoimmunopathy, rejection reaction and tumors is prepared from IL-18 as target moleculae and the actigve fragment PE38 of pseudomonas aeruginosa's exotoxin through configuring recombinant plasmid, preparing engineering bacteria transfected by said plasmid, expressing immunotoxin IL-18-PE38 and purifying. Its advantage is hightarget kill to TH1 cells.

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

The invention relates to a recombinant immunotoxin and a preparation method and application thereof, the recombinant immunotoxin is a fusion protein of a toxic molecule and a carrier molecule, the toxic molecule is pumpkin protein or a pumpkin protein mutant, the recombinant immunotoxin is the fusion protein expressed by connection of the pumpkin protein or a pumpkin protein mutant gene with an antibody or a cytokine gene capable of binding to target cells (including tumor cells, pathogenic cells, and the like), the anti-tumor activity of the recombinant immunotoxin and the anti-tumor activityof the recombinant immunotoxin in treatment of rejection reaction after organ transplant, autoimmune diseases, and possible indications such as infectious diseases caused by pathogens are tested to prove that the recombinant immunotoxin is superior to the toxic molecule and the carrier molecule.

The present invention relates to new recombinant humanized immunotoxin hS83-P34, which contains fusion protein comprising the antigen associated molecule of humanized cytotoxic T cell antigen 4 and human porforin channel forming active molecule. The immunotoxin of the present invention has strict targeting, less tendency of damaging health cell, less toxic side effect, no need of internalization and intracellular transport, high acting efficiency, less likelihood of generating corresponding antibody, weak immunogenicity and less tendency of generating drug resistance. It may be used in treating some tumors and autoimmune diseases and suppressing immunologic rejection reaction in organ transplantation.

The high efficiency expression plasmid of recombinant immune toxin IP10-DT390 constituted by means of gene engineering technology is for activated Th1 cell specifically. After transfected into body, the immune toxin plasmid expresses high specific recombinant immune toxin with IP10 as targeting molecule, active diphtherin segment DT390 as toxin molecule and the specific membrane acceptor CXCR3 of activated Th1 cell as the target point. The preparation process of the immune toxin plasmid includes the constitution of recombinant plasmid, the preparation of recombinant plasmid transfected engineering bacterium and other steps. The plasmid expressed recombinant immune toxin has strict targeting property of attacking activated Th1 cell specifically by means of targeting IP10 to induce specific immunity tolerance and avoid killing normal T cells, and is especially suitable for preventing and treating of autoimmune disease and organ transplantation rejection, and some tumors.

The invention relates to an anittumor recombinant immunotoxin, preparation method and application thereof. The invention constructs a targeting toxin fusion, which contains amino acid fragment of luffin S2, human gonadotropin-releasing hormone and intermediate connecting peptide. The preparation method of the fusion includes (1) constructing plasmid containing objective gene; (2) transforming to express in Escherichia coli; (3) centrifuging to collect thallus, ultrasonic cracking, and washing to obtain crude inclusion body; and (4) dialyzing, performing affinity chromatography, excising His label and eliminating Xa factor.. The targeting toxin fusion has strong cell cytotoxic, less usage dosage and low product cost, which is effective in inhibiting tumor in early growth stage and tumor in middle growth stage; and is adaptable to the therapy of solid tumor such as breast cancer, oophoroma, endometrial carcinoma, prostatic cancer, etc.

The invention discloses anti-rat CD3 recombinant immunotoxin as well as a preparation method and application thereof and belongs to the technical field of biology. A genetic engineering technology anda genetic engineering strategy are adopted, and a combination manner of a single-chain antibody and DT390 is changed to improve the affinity; codon series are optimized to obtain three types of recombinant immunotoxin which take a DT structure as a toxic center, and a prokaryotic expression system is constructed; anti-rat single-chain antibody coupled immunotoxin of a targeting T cell receptor CD3epsilon is obtained and T lymphocytes of a peripheral immune organ are eliminated; a transplanting immune model is established by utilizing the immunotoxin, and treatment researches including immunetolerance, autoimmune diseases and the like are carried out. The anti-rat CD3 recombinant immunotoxin proves the effectiveness of eliminating rat peripheral blood and lymph node T cells by the targeting anti-rat CD3epsilon recombinant immunotoxin. The anti-rat CD3 recombinant immunotoxin has application meanings in the aspects of researches of eliminating the rat T lymphocytes, treating the autoimmune diseases, transplanting the organs, treating immune tolerance and treating tumors, and possibly has a potential of pre-clinical pharmaceutical researches and conversion subsequently.

In the invention, selecting MIP-1alpha as guide molecule, active segment DT390 of diphtheria toxin as toxin molecule, constructing eukaryon plasmid of MIP-1alpha-DT390 recombination immunotoxin, and expressing the product in transfection animal body. The experiments show: the recombination immunotoxin MIP-1alpha-DT390 has character to special attack and kill activated Th1 cell while no effect to Th2 and B cells. After curing by the product, the clinical symptom of EAE is released obviously; the pathological section shows that compared with un-cured group, in the cured group, the cerebellum and spinal demyelination lesions reduces, meninges and vein peripheral lymphocyte infiltration decreases.